Generation of Metastatic Cholangiocarcinoma Patient-Derived Xenograft Models
Mariana Yáñez-Bartolomé(Hebron University), Tian V. Tian(Breast Cancer Research Foundation), Queralt Serra-Camprubí(Vall d'Hebron Institut de Recerca), Florian Castet(Institut d'Investigació Biomédica de Bellvitge), Marta Escorihuela(Vall d'Hebron Institut de Recerca), Joaquı́n Arribas(Hospital Del Mar), Teresa Macarulla(Vall d'Hebron Hospital Universitari), Sandra Peiró(Vall d'Hebron Institute of Oncology), Jessica Querol(Vall d'Hebron Institut de Recerca), Carles Fabregat-Franco(Vall d'Hebron Institut de Recerca), Enrique J. Arenas(Vall d'Hebron Institut de Recerca)
Cited by 2
Related Papers
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
|Annals of Oncology|2018|424
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
|The Lancet. Gastroenterology & hepatology|2021|423
Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial‐to‐mesenchymal transition
|International Journal of Cancer|2013|350